...
首页> 外文期刊>European journal of endocrinology >Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study
【24h】

Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study

机译:Graves甲状腺功能亢进症接受放射碘治疗的患者早期服用左甲状腺素的生活质量,临床结局和安全性:一项随机对照研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective While radioiodine therapy is commonly used for treating Graves' disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT _( 4 ) ) treatment in the early post-therapeutic period may be an interesting approach to limit this phenomenon. Methods A multicenter, prospective, open-label randomized controlled trial enrolled 94 patients with Graves' hyperthyroidism randomly assigned to the experimental group ( n =46) (group A: early prophylactic LT _( 4 ) treatment) or the control group ( n =48) (group B: standard follow-up). The primary endpoint was the 6-month QoL. The secondary endpoints were other QoL scores such as Graves' ophthalmopathy (GO) outcomes, thyroid function tests and safety. Results The primary endpoint at 6 months was achieved: the mental composite score (MCS) of Short Form 36 (SF-36) was significantly higher in group A compared to group B ( P =0.009). Four other dimension scores of the SF-36 and four dimension scores of the thyroid-specific patient-reported outcome (ThyPRO) significantly differed between the two groups, indicating better QoL in group A. After adjustment for variables, the early LT _( 4 ) administration strategy was found as an independent factor for only two scores of SF-36: the MCS and the general health (GH) score. There were no differences in GO, final thyroid status and changes in the anti-TSH receptor antibodies (TRAbs) levels between the two groups. No adverse cardiovascular event was reported. Conclusion Early LT _( 4 ) administration post-radioactive iodine (RAI) could represent a safe potential benefit for patients with regard to QoL. The optimal strategy taking into account administered RAI activities and LT _( 4 ) treatment dosage and timing remains to be determined.
机译:目的尽管放射性碘疗法通常用于治疗Graves病,但长期的临床甲状腺功能减退症可能导致残疾症状,从而导致患者生活质量(QoL)下降。在治疗后早期引入左甲状腺素(LT _(4))治疗可能是限制这种现象的有趣方法。方法一项多中心,前瞻性,开放标签的随机对照试验纳入了94例Graves甲状腺功能亢进症患者,随机分为实验组(n = 46)(A组:早期LT _(4)预防性治疗)或对照组(n = 48)(B组:标准随访)。主要终点为六个月的生活质量。次要终点是其他QoL评分,例如Graves眼病(GO)结果,甲状腺功能检查和安全性。结果达到了6个月的主要终点:A组的简短表格36(SF-36)的心理综合评分(MCS)明显高于B组(P = 0.009)。两组之间SF-36的其他四个维度评分和甲状腺特异患者报告的结局(ThyPRO)的四个维度评分均存在显着差异,表明A组的QoL更好。调整变量后,早期LT _(4 )管理策略仅是SF-36的两个得分的独立因素:MCS和总体健康(GH)得分。两组之间的GO,最终甲状腺状态以及抗TSH受体抗体(TRAbs)水平没有差异。没有不良心血管事件的报道。结论放射性碘(RAI)后早期给予LT_(4)可能代表QoL患者安全的潜在获益。考虑到管理的RAI活动和LT_(4)治疗剂量和时机的最佳策略仍有待确定。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号